The effect of serum pretreatment regimens for the detection of HLA class I antibodies in platelet-refractory patients

Biomedical Excellence for Safer Transfusion (BEST) Collaborative

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

BACKGROUND: Single antigen bead (SAB) assays are used to identify human leukocyte antigen (HLA) antibodies in patients with platelet refractoriness due to HLA Class I alloimmunization. Some laboratories use serum pretreatment regimens to eliminate interference from immunoglobulin M antibodies and complement. These modifications may contribute to interlaboratory variability, which is a recognized problem with the SAB assay.

STUDY DESIGN AND METHODS: Five patients' sera were overnight shipped to 12 laboratories in the United States and internationally. Recipients used their lab's SAB procedure to identify HLA Class I antibodies. The resultant mean fluorescence intensity (MFI) data were compared by instrumentation, bead lot, and pretreatment regimens. Laboratory-specific cutoffs for positive antibodies were applied to the results.

RESULTS: Interlaboratory variability for MFI values appears to be associated with different pretreatment regimens. The coefficient of variation (CV) of MFI from samples pretreated with ethylenediaminetetraacetic acid, dithiothreitol, or heat inactivation (EDHI) were similar, ranging from 14% to 56% (mean, 22%). For samples with no pretreatment, the CVs were significantly higher than EDHI-treated samples, ranging from 25% to 74% (mean, 39%; 95% confidence interval, 12.10-21.90; p < 0.0001). An intralaboratory comparison of pretreatment regimens confirmed these findings. Some positive antibody specificities present in EDHI-treated samples were negative in corresponding samples with no pretreatment when laboratory-specific cutoffs for positive antibodies were applied.

CONCLUSION: Our results show that greater interlaboratory precision can be achieved when samples are pretreated with EDHI as opposed to no pretreatment, likely because these pretreatments eliminate interference from inhibitors. Inhibitors may mask antibodies, leading to missed (or uncalled) specificities when no pretreatment is used.

Original languageEnglish (US)
Pages (from-to)488-497
Number of pages10
JournalTransfusion
Volume60
Issue number3
DOIs
StatePublished - Mar 2020

Bibliographical note

Funding Information:
The funds to cover shipment costs were provided by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative.The authors gratefully acknowledge the contributions of the following people: Fumihiro Azuma, Jonathon Barone, Donna-Sue Hain, Ayesha Iqbal, Patricia Kopko, Ronald Lofy, Joanne Pink, Rebecca Scammell, John Skibby, Selina Taylor, and Rita Font?o Wendel.

Publisher Copyright:
© 2020 AABB

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'The effect of serum pretreatment regimens for the detection of HLA class I antibodies in platelet-refractory patients'. Together they form a unique fingerprint.

Cite this